期刊文献+

拉米夫定联合扶正复肝方治疗慢性乙型肝炎及对拉米夫定耐药的影响研究

Study of Lamivudine combined with Fuzheng-Fugan decoction on chronic type B hepatitis and effect on drug fast
下载PDF
导出
摘要 目的观察拉米夫定联合扶正复肝方治疗慢性乙型肝炎的疗效和对拉米夫定耐药的影响。方法将78例慢性乙型肝炎(HBV-DNA阳性)患者,随机分为2组:对照组予拉米夫定治疗,治疗组予拉米夫定加扶正复肝方治疗,分别检测血清肝脏生化指标,HBV-DNA阳性率和对拉米夫定的耐药情况。结果在治疗52周时,治疗组血清丙氨酸氨基转移酶复常率和HBV-DNA阴转率比对照组高,耐药率低。结论拉米夫定加扶正复肝方能有效提高慢性乙型肝炎的疗效,并减少拉米夫定的耐药率。 Objective It is to observe the curative effect of Lamivudine combined with Fuzheng- Fugan decoction on chronic type B hepatitis and effect on drug fast of Lamivudine, Methods 78 cases of patients with chronic type B hepatitis whose HBV - DNA was positive were chosen and randomly divided into 2 groups, Control group was given Lamivudine, and treatment group was added with Fuzheng- Fugan decoction on the treatment above, Then serum liver biochemistry indexes were determined and positive rate of HBV - DNA, drug fast of Lamivudine were observed, Results The rate of normal serum ALT and negative rate of HBV - DNA were higher and the drug fast rate was lower in treatment group than that in control group after treating for 52 weeks. Conclusion Lamivudine combined with Fuzheng- Fugan decoction can effectively enhance the curative effect on chronic type B hepatitis and can low down the drug fast.
出处 《现代中西医结合杂志》 CAS 2007年第31期4596-4597,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 拉米夫定 扶正复肝方 慢性乙型肝炎 耐药率 Lamivudine Fuzheng- Fugan decoction chronic type B hepatitis drug fast rate
  • 相关文献

参考文献3

二级参考文献24

  • 1Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 2Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 3Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 4Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 5Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 7Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 8Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 9Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
  • 10Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Seminars in liver disease. 2003 23: 89-100.

共引文献14156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部